Phase I
A Phase 1 Trial of TGN-S11 in Patients With Human Papillomavirus (HPV)-Associated Relapsed, Resistant or Metastatic Cancer
- Study HIC#:2000036416
- Last Updated:08/16/2024
This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers. The Expansion Phase will begin in parallel one dose level lower than the highest dose deemed safe in the Dose Escalation in combination with a PD-1 checkpoint blockade.
- Age18 years and older
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Anna Wu
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
Inclusion Criteria:
- Prior histologically confirmed HPV-associated squamous cell carcinoma, which is relapsed, resistant, or metastatic
- Life expectancy of at least 3 months
- Dose Escalation Phase: patients who have experienced disease progression on Standard of Care Therapies
Exclusion Criteria:
- Active CNS metastases
- Have any history of seizure disorder or are taking prophylactic seizure medication
- Have an active viral, bacterial, or fungal infection
